Divergent Oxidative Stress in Normal Tissues and Inflammatory Cells in Hodgkin and Non-Hodgkin Lymphoma.
2-NBDG
FDG-PET/CT
endoplasmic reticulum
lymphoma
mitochondria
pentose phosphate pathway
redox stress
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Jul 2023
07 Jul 2023
Historique:
received:
01
06
2023
revised:
04
07
2023
accepted:
05
07
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Previous studies reported mitochondrial and endoplasmic reticulum redox stress in peripheral blood mononucleated cells (PBMCs) of treatment-naïve Hodgkin lymphoma (HL) patients. Here, we assessed whether this response also applies to non-HL (NHL) patients, and whether the oxidative damage is a selective feature of PBMCs or, rather, also affects tissues not directly involved in the inflammatory response. Isolated PBMCs of 28 HL, 9 diffuse large B cell lymphoma, 8 less aggressive-NHL, and 45 controls underwent flow cytometry to evaluate redox stress and uptake of the glucose analogue 2-NBDG. This analysis was complemented with the assay of malondialdehyde (MDA) levels and enzymatic activity of glucose-6P-dehydrogenase and hexose-6P-dehydrogenase (H6PD). In all lymphoma patients, Mitochondrial reactive oxygen species generation and MDA levels were increased only in HL patients as well as H6PD activity and 2-NBDG uptake. Similarly, myocardial FDG retention was higher in HL than in other groups as opposed to a similar tracer uptake in the skeletal muscle. Redox stress of PBMCs is more pronounced in HL with respect to both NHL groups. This phenomenon is coherent with an increased activity of H6PD that also extends to the myocardium.
Sections du résumé
BACKGROUND
BACKGROUND
Previous studies reported mitochondrial and endoplasmic reticulum redox stress in peripheral blood mononucleated cells (PBMCs) of treatment-naïve Hodgkin lymphoma (HL) patients. Here, we assessed whether this response also applies to non-HL (NHL) patients, and whether the oxidative damage is a selective feature of PBMCs or, rather, also affects tissues not directly involved in the inflammatory response.
METHODS
METHODS
Isolated PBMCs of 28 HL, 9 diffuse large B cell lymphoma, 8 less aggressive-NHL, and 45 controls underwent flow cytometry to evaluate redox stress and uptake of the glucose analogue 2-NBDG. This analysis was complemented with the assay of malondialdehyde (MDA) levels and enzymatic activity of glucose-6P-dehydrogenase and hexose-6P-dehydrogenase (H6PD). In all lymphoma patients,
RESULTS
RESULTS
Mitochondrial reactive oxygen species generation and MDA levels were increased only in HL patients as well as H6PD activity and 2-NBDG uptake. Similarly, myocardial FDG retention was higher in HL than in other groups as opposed to a similar tracer uptake in the skeletal muscle.
CONCLUSIONS
CONCLUSIONS
Redox stress of PBMCs is more pronounced in HL with respect to both NHL groups. This phenomenon is coherent with an increased activity of H6PD that also extends to the myocardium.
Identifiants
pubmed: 37444643
pii: cancers15133533
doi: 10.3390/cancers15133533
pmc: PMC10341255
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Italian Association for Cancer Research
ID : IG 23201
Références
Expert Rev Hematol. 2013 Jun;6(3):317-25
pubmed: 23782085
Methods Mol Biol. 1994;32:9-15
pubmed: 7951753
Metabolites. 2021 Dec 21;12(1):
pubmed: 35050128
Proc Natl Acad Sci U S A. 2015 Mar 3;112(9):2835-40
pubmed: 25730877
J Nucl Cardiol. 2020 Dec;27(6):2183-2194
pubmed: 30737636
EJNMMI Res. 2020 Jul 7;10(1):76
pubmed: 32638178
J Proteome Res. 2011 Jan 7;10(1):113-9
pubmed: 20886858
Antioxidants (Basel). 2020 Dec 01;9(12):
pubmed: 33271863
Mol Metab. 2020 Jan;31:98-108
pubmed: 31918925
J Nucl Med. 2007 Oct;48(10):1662-9
pubmed: 17873124
Biomedicines. 2021 Aug 06;9(8):
pubmed: 34440175
Transl Oncol. 2020 May;13(5):100752
pubmed: 32302773
J Biol Chem. 2000 Jun 16;275(24):18489-94
pubmed: 10764804
J Nucl Med. 2017 Oct;58(10):1638-1645
pubmed: 28646013
Clin Exp Immunol. 2015 Oct;182(1):69-80
pubmed: 26032049
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1184-1196
pubmed: 30617965
Biol Chem. 2010 Jan;391(1):1-8
pubmed: 19804362
Methods Mol Biol. 2016;1304:53-61
pubmed: 25092056
Sci Rep. 2016 Apr 28;6:25092
pubmed: 27121192
Antioxidants (Basel). 2021 Aug 30;10(9):
pubmed: 34573024
Semin Hematol. 1999 Jul;36(3):253-9
pubmed: 10462325
Clin Exp Immunol. 1991 Sep;85(3):436-40
pubmed: 1893624
Antioxidants (Basel). 2022 Apr 11;11(4):
pubmed: 35453447
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Front Oncol. 2022 Oct 13;12:964573
pubmed: 36313712